GeneDx Reports 101% Revenue Growth in Q4

GeneDx Holdings Corp reported strong financial performance in its recent Q4 earnings call, showcasing a revenue of $95.3 million, up 64% year-over-year, driven primarily by its exome and genome testing services. The company experienced a significant gross margin expansion, achieving an adjusted gross margin of 70%, up from 56% a year prior. Following these results, shares surged by 24%, reflecting investor confidence in the company's growth potential. Analysts have raised their price targets for GeneDx, with Craig-Hallum increasing it to $114 from $95, citing conservative revenue guidance for 2025 amid promising growth drivers. The stock has demonstrated extraordinary performance over the past year, climbing nearly 1800%. Overall, the company has garnered a 'Moderate Buy' rating from analysts, with plans for continued strategic investments to capitalize on its strong market position.